Cretostimogene + Nivolumab
Muscle-Invasive Bladder Cancer (MIBC)
Phase 2Active (Investigator-sponsored)
Key Facts
Indication
Muscle-Invasive Bladder Cancer (MIBC)
Phase
Phase 2
Status
Active (Investigator-sponsored)
Company
About CG Oncology
CG Oncology is a late-stage biopharma company with a mission to deliver innovative, bladder-sparing immunotherapies for patients with non-muscle invasive bladder cancer (NMIBC). Its lead asset, cretostimogene grenadenorepvec, an intravesical oncolytic immunotherapy, has garnered FDA Fast Track and Breakthrough Therapy designations and is in a pivotal Phase 3 program. The company's strategy is intensely focused on successfully commercializing this potential backbone therapy in a significant market with limited effective options for BCG-unresponsive patients.
View full company profileTherapeutic Areas
Other Muscle-Invasive Bladder Cancer (MIBC) Drugs
| Drug | Company | Phase |
|---|---|---|
| Decipher Bladder | Decipher Biosciences | Commercial |
| ZH9 + Checkpoint Inhibitors | Prokarium | Discovery/Preclinical |
| NDV-01 | Relmada Therapeutics | Pre-Clinical / Phase 2 Planned |